A Dual GLP-1/GIP Receptor Agonist Is More Effective than Liraglutide in the A53T Mouse Model of Parkinson's Disease.
Journal Information
Full Title: Parkinsons Dis
Abbreviation: Parkinsons Dis
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Clinical Neurology
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflicts of Interest CH is a named inventor on patents that cover the use of GLP-1/GIP receptor agonists in treating neurodegenerative disorders. He is the CSO of the company Kariya Pharmaceuticals. The other authors declare that they have no conflicts of interest."
"This work was supported by the Natural Science Foundation of China (U1504829), doctoral fund of Henan University of Chinese Medicine (BSJJ2022-09), Scientific and Technological Innovation Team Support Program for Colleges and Universities in Henan Province (21IRTSTHN026), and Joint Research Fund of Science and Technology R&D Plan of Henan Province (222301420068)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025